Standard
Doxorubicin delivery systems based on polypeptide nanoparticles for subcutaneous administration in cancer therapy. / Sudareva, N.N.; Tarasenko, I. I.; Suslov, D.N.; Suvorova, Olga M.; Колбе, Константин Андреевич; Yukina, Galina Y.; Tyndyk, Margarita L.; Zmitrichenko, Iulia G.; Коржикова-Влах, Евгения Георгиевна.
In:
Mendeleev Communications, Vol. 34, No. 1, 2024, p. 18-21.
Research output: Contribution to journal › Article › peer-review
Harvard
Sudareva, NN, Tarasenko, II, Suslov, DN, Suvorova, OM, Колбе, КА, Yukina, GY, Tyndyk, ML, Zmitrichenko, IG
& Коржикова-Влах, ЕГ 2024, '
Doxorubicin delivery systems based on polypeptide nanoparticles for subcutaneous administration in cancer therapy',
Mendeleev Communications, vol. 34, no. 1, pp. 18-21.
https://doi.org/10.1016/j.mencom.2024.01.006APA
Sudareva, N. N., Tarasenko, I. I., Suslov, D. N., Suvorova, O. M., Колбе, К. А., Yukina, G. Y., Tyndyk, M. L., Zmitrichenko, I. G.
, & Коржикова-Влах, Е. Г. (2024).
Doxorubicin delivery systems based on polypeptide nanoparticles for subcutaneous administration in cancer therapy.
Mendeleev Communications,
34(1), 18-21.
https://doi.org/10.1016/j.mencom.2024.01.006Vancouver
Author
Sudareva, N.N. ; Tarasenko, I. I. ; Suslov, D.N. ; Suvorova, Olga M. ; Колбе, Константин Андреевич ; Yukina, Galina Y. ; Tyndyk, Margarita L. ; Zmitrichenko, Iulia G.
; Коржикова-Влах, Евгения Георгиевна. /
Doxorubicin delivery systems based on polypeptide nanoparticles for subcutaneous administration in cancer therapy. In:
Mendeleev Communications. 2024 ; Vol. 34, No. 1. pp. 18-21.
BibTeX
@article{2d02c081e16b43c59fc82e9edcf29fbf,
title = "Doxorubicin delivery systems based on polypeptide nanoparticles for subcutaneous administration in cancer therapy",
abstract = "Polypeptide-based doxorubicin delivery systems were prepared and their physicochemical and functional properties, such as size, encapsulation efficiency, stability, release of doxorubicin in various media and cytotoxicity, were characterized. An in vivo study revealed an effective reduction of tumor growth when these systems were administered subcutaneously.",
keywords = "cancer treatment, delivery systems, doxorubicin, nanoparticles, subcutaneous administration, synthetic polypeptides",
author = "N.N. Sudareva and Tarasenko, {I. I.} and D.N. Suslov and Suvorova, {Olga M.} and Колбе, {Константин Андреевич} and Yukina, {Galina Y.} and Tyndyk, {Margarita L.} and Zmitrichenko, {Iulia G.} and Коржикова-Влах, {Евгения Георгиевна}",
year = "2024",
doi = "10.1016/j.mencom.2024.01.006",
language = "English",
volume = "34",
pages = "18--21",
journal = "Mendeleev Communications",
issn = "0959-9436",
publisher = "Elsevier",
number = "1",
}
RIS
TY - JOUR
T1 - Doxorubicin delivery systems based on polypeptide nanoparticles for subcutaneous administration in cancer therapy
AU - Sudareva, N.N.
AU - Tarasenko, I. I.
AU - Suslov, D.N.
AU - Suvorova, Olga M.
AU - Колбе, Константин Андреевич
AU - Yukina, Galina Y.
AU - Tyndyk, Margarita L.
AU - Zmitrichenko, Iulia G.
AU - Коржикова-Влах, Евгения Георгиевна
PY - 2024
Y1 - 2024
N2 - Polypeptide-based doxorubicin delivery systems were prepared and their physicochemical and functional properties, such as size, encapsulation efficiency, stability, release of doxorubicin in various media and cytotoxicity, were characterized. An in vivo study revealed an effective reduction of tumor growth when these systems were administered subcutaneously.
AB - Polypeptide-based doxorubicin delivery systems were prepared and their physicochemical and functional properties, such as size, encapsulation efficiency, stability, release of doxorubicin in various media and cytotoxicity, were characterized. An in vivo study revealed an effective reduction of tumor growth when these systems were administered subcutaneously.
KW - cancer treatment
KW - delivery systems
KW - doxorubicin
KW - nanoparticles
KW - subcutaneous administration
KW - synthetic polypeptides
UR - https://www.mendeley.com/catalogue/ceadff48-1556-386e-858d-1d2bf28b0267/
U2 - 10.1016/j.mencom.2024.01.006
DO - 10.1016/j.mencom.2024.01.006
M3 - Article
VL - 34
SP - 18
EP - 21
JO - Mendeleev Communications
JF - Mendeleev Communications
SN - 0959-9436
IS - 1
ER -
